Azasetron

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Azasetron
Azasetron.png
Clinical data
AHFS/Drugs.com International Drug Names
Routes of
administration
Oral
ATC code
  • none
Pharmacokinetic data
Bioavailability 90%
Excretion 60-70%
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C17H20ClN3O3
Molar mass 349.81 g/mol
3D model (JSmol)
  (verify)

Azasetron is an antiemetic which acts as a 5-HT3 receptor antagonist, pKi = 9.27 [1] It is used in the management of nausea and vomiting induced by cancer chemotherapy (such as cisplatin chemotherapy). Azasetron hydrochloride is given in a usual dose of 10 mg once daily by mouth or intravenously. It is approved for marketing in Japan, and marketed exclusively by Torii Pharmaceutical Co., Ltd. under the trade names "Serotone I.V. Injection 10 mg" and "Serotone Tablets 10 mg".[2] Pharmacokinetics data from S. Tsukagoshi.[3]

References[edit]

  1. ^ "Azasetron". drugcentral.org/. UNM School of Medicine. 2016-07-31. Retrieved 2016-11-11. 
  2. ^ "Torii Pharmaceutical to Solely Market Antiemetic Drugs". Torii Pharmaceutical Co Ltd. 2009-01-13. Retrieved 2016-11-11. 
  3. ^ Tsukagoshi, S. (1999-06-01). "[Pharmacokinetics of azasetron (Serotone), a selective 5-HT3 receptor antagonist]". Gan to Kagaku Ryoho. Cancer & Chemotherapy. 26 (7): 1001–1008. ISSN 0385-0684. PMID 10396331.